Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target

Compare

844 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SNDX Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Syndax

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SNDX Stock 12 Month Forecast

Average Price Target

$35.00

▲(166.97% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Syndax Pharmaceuticals in the last 3 months. The average price target is $35.00 with a high forecast of $56.00 and a low forecast of $17.00. The average price target represents a 166.97% change from the last price of $13.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","32":"$32","57":"$57","19.5":"$19.5","44.5":"$44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,19.5,32,44.5,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.68,18.78153846153846,21.88307692307692,24.984615384615385,28.086153846153845,31.187692307692306,34.28923076923077,37.39076923076923,40.49230769230769,43.59384615384615,46.69538461538461,49.79692307692307,52.89846153846154,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.68,17.166153846153847,18.65230769230769,20.138461538461538,21.624615384615385,23.11076923076923,24.596923076923076,26.083076923076923,27.56923076923077,29.055384615384614,30.54153846153846,32.027692307692305,33.51384615384615,{"y":35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.68,15.781538461538462,15.883076923076922,15.984615384615385,16.086153846153845,16.18769230769231,16.28923076923077,16.39076923076923,16.49230769230769,16.593846153846155,16.695384615384615,16.796923076923076,16.89846153846154,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.89,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$56.00

Average Price Target$35.00

Lowest Price Target$17.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andres Y. Maldonado

H.C. Wainwright

$40

Buy

205.11%

Upside

Reiterated

10/27/25

Buy Rating for Syndax Pharmaceuticals Driven by FDA Approval of Revuforj and Market Expansion PotentialValuation and risks to achievement of price target. Our 12-month price target of $40 is based on an equally weighted composite of (a) $41.89/share, as a 15x multiple of taxed and diluted FY32 GAAP EPS of $6.17 discounted at 12%, and (b) an NPV of $39.0/share (discount rate 12.0%, growth rate 2.0%). The assumptions are in line with the expected P/E multiple and discount rate of a commercial-stage biopharmaceutical company. Risks to achieving our price target include the following: 1) Clinical risk.

Jason Zemansky

Bank of America Securities

$26→$27

Buy

105.95%

Upside

Reiterated

10/27/25

Buy Rating Reaffirmed for Syndax Pharmaceuticals Despite Black Box Warning on Revuforj

Stephen Willey

Stifel Nicolaus

$44

Buy

235.62%

Upside

Reiterated

10/27/25

Stifel Nicolaus Remains a Buy on Syndax Pharmaceuticals (SNDX)We remain Buy-rated.

Peter Lawson

Barclays

$19

Buy

44.93%

Upside

Reiterated

10/27/25

Barclays Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)

Justin Zelin

BTIG

$56

Buy

327.15%

Upside

Reiterated

10/26/25

Syndax Pharmaceuticals (SNDX) Gets a Buy from BTIG

Mayank Mamtani

B. Riley Securities

$33

Buy

151.72%

Upside

Reiterated

10/03/25

Syndax Pharmaceuticals (SNDX) Gets a Buy from B. Riley Securities

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

09/19/25

Corinne Johnson

Goldman Sachs

$20→$24

Buy

83.07%

Upside

Reiterated

09/08/25

Syndax Pharmaceuticals (SNDX) Receives a Buy from Goldman Sachs

Bradley Canino

Guggenheim

$34

Buy

159.34%

Upside

Initiated

09/03/25

Syndax assumed with a Buy at GuggenheimSyndax assumed with a Buy at Guggenheim

Yigal Nochomovitz

Citi

$46→$51

Buy

289.02%

Upside

Reiterated

08/06/25

Citi ups Syndax target, opens 'upside catalyst watch'Citi ups Syndax target, opens 'upside catalyst watch'

Anupam Rama

J.P. Morgan

$39→$40

Buy

205.11%

Upside

Reiterated

08/06/25

Syndax Pharmaceuticals (SNDX) Gets a Buy from J.P. Morgan

George Farmer

Scotiabank

$17

Hold

29.67%

Upside

Reiterated

08/05/25

Syndax Pharmaceuticals (SNDX) Gets a Hold from Scotiabank

David Dai

UBS

$37→$35

Buy

166.97%

Upside

Reiterated

07/15/25

Syndax price target lowered to $35 from $37 at UBSSyndax price target lowered to $35 from $37 at UBS

Kelly Shi

Jefferies

$43

Buy

227.99%

Upside

Reiterated

06/05/25

Syndax Pharmaceuticals: Promising 2025 Outlook and Strategic Product Launches Drive Buy Rating

Salim Syed

Mizuho Securities

$45

Buy

243.25%

Upside

Reiterated

05/16/25

Mizuho Securities Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andres Y. Maldonado

H.C. Wainwright

$40

Buy

205.11%

Upside

Reiterated

10/27/25

Jason Zemansky

Bank of America Securities

$26→$27

Buy

105.95%

Upside

Reiterated

10/27/25

Buy Rating Reaffirmed for Syndax Pharmaceuticals Despite Black Box Warning on Revuforj

Stephen Willey

Stifel Nicolaus

$44

Buy

235.62%

Upside

Reiterated

10/27/25

Stifel Nicolaus Remains a Buy on Syndax Pharmaceuticals (SNDX)We remain Buy-rated.

Peter Lawson

Barclays

$19

Buy

44.93%

Upside

Reiterated

10/27/25

Barclays Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)

Justin Zelin

BTIG

$56

Buy

327.15%

Upside

Reiterated

10/26/25

Syndax Pharmaceuticals (SNDX) Gets a Buy from BTIG

Mayank Mamtani

B. Riley Securities

$33

Buy

151.72%

Upside

Reiterated

10/03/25

Syndax Pharmaceuticals (SNDX) Gets a Buy from B. Riley Securities

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

09/19/25

Corinne Johnson

Goldman Sachs

$20→$24

Buy

83.07%

Upside

Reiterated

09/08/25

Syndax Pharmaceuticals (SNDX) Receives a Buy from Goldman Sachs

Bradley Canino

Guggenheim

$34

Buy

159.34%

Upside

Initiated

09/03/25

Syndax assumed with a Buy at GuggenheimSyndax assumed with a Buy at Guggenheim

Yigal Nochomovitz

Citi

$46→$51

Buy

289.02%

Upside

Reiterated

08/06/25

Citi ups Syndax target, opens 'upside catalyst watch'Citi ups Syndax target, opens 'upside catalyst watch'

Anupam Rama

J.P. Morgan

$39→$40

Buy

205.11%

Upside

Reiterated

08/06/25

Syndax Pharmaceuticals (SNDX) Gets a Buy from J.P. Morgan

George Farmer

Scotiabank

$17

Hold

29.67%

Upside

Reiterated

08/05/25

Syndax Pharmaceuticals (SNDX) Gets a Hold from Scotiabank

David Dai

UBS

$37→$35

Buy

166.97%

Upside

Reiterated

07/15/25

Syndax price target lowered to $35 from $37 at UBSSyndax price target lowered to $35 from $37 at UBS

Kelly Shi

Jefferies

$43

Buy

227.99%

Upside

Reiterated

06/05/25

Syndax Pharmaceuticals: Promising 2025 Outlook and Strategic Product Launches Drive Buy Rating

Salim Syed

Mizuho Securities

$45

Buy

243.25%

Upside

Reiterated

05/16/25

Mizuho Securities Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Syndax Pharmaceuticals

1 Month

xxx

Success Rate

8/16 ratings generated profit

Average Return

+2.51%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +2.51% per trade.

3 Months

xxx

Success Rate

7/16 ratings generated profit

Average Return

+1.33%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 43.75% of your transactions generating a profit, with an average return of +1.33% per trade.

1 Year

Justin ZelinBTIG

Success Rate

8/16 ratings generated profit

Average Return

-3.24%

reiterated a buy rating 3 days ago

Copying Justin Zelin's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -3.24% per trade.

2 Years

xxx

Success Rate

4/12 ratings generated profit

Average Return

+0.73%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of +0.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SNDX Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SNDX has received 15 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SNDX average Analyst price target in the past 3 months is 35.00.

Each month's total comprises the sum of three months' worth of ratings.

SNDX Financial Forecast

SNDX Earnings Forecast

Next quarter’s earnings estimate for SNDX is -$0.72 with a range of -$0.97 to -$0.54. The previous quarter’s EPS was -$0.83. SNDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year SNDX has Preformed in-line its overall industry.

SNDX Sales Forecast

Next quarter’s sales forecast for SNDX is $48.01M with a range of $40.50M to $60.17M. The previous quarter’s sales results were $37.96M. SNDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year SNDX has Preformed in-line its overall industry.

SNDX Stock Forecast FAQ

What is SNDX’s average 12-month price target, according to analysts?

Based on analyst ratings, Syndax Pharmaceuticals Inc’s 12-month average price target is 35.00.

What is SNDX’s upside potential, based on the analysts’ average price target?

Syndax Pharmaceuticals Inc has 166.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SNDX a Buy, Sell or Hold?

Syndax Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is Syndax Pharmaceuticals Inc’s price target?

The average price target for Syndax Pharmaceuticals Inc is 35.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $56.00 ,the lowest forecast is $17.00. The average price target represents 166.97% Increase from the current price of $13.11.

What do analysts say about Syndax Pharmaceuticals Inc?

Syndax Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of SNDX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target

SNDX Analyst Ratings

SNDX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Syndax Pharmaceuticals

SNDX Analyst Recommendation Trends

SNDX Financial Forecast

SNDX Earnings Forecast

SNDX Sales Forecast

SNDX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts